International Business - Biocon Ltd.

...

Biocon Pharma Inc.

Based in United States, Biocon Pharma Inc. is a step down subsidiary of Biocon Limited by Biocon Pharma Limited. Incorporated in July 2015, Biocon Pharma Inc. takes part in commercialising pharmaceutical drugs in the United States.

Biocon SA

Based in Switzerland, Biocon SA is a subsidiary of Biocon Limited. It takes part in developing and commercialising insulin products for purchase in the global market through a variety of partnered and internal programmes. It also holds the marketing rights for the insulin products in the company’s product portfolio. Besides that, Biocon SA is also involved in discovering, developing, commercialising and licensing novel drugs through strategic partnerships. During 2016, Biocon SA sold its shareholdings in Biocon Sdn Bhd of Malaysia to Biocons Biologics Limited of United Kingdom (Bloomberg.com, 2016a).

Biocon Biologics Limited

Based in United Kingdom, Biocon Biologics Limited is a subsidiary of Biocon Limited. It was incorporated in March 2016. It is used to house biosimilar medical products of Biocon. In 2016, Biocon Sdn Bhd of Malaysia became its wholly owned subsidiary through equity stake acquisition from Biocon Limited and Biocon SA.

Biocon SDN BHD

Based in Malaysia, Biocon Sdn Bhd is a step down subsidiary of Biocon Limited by Biocon Biologics Limited. It is the company’s first establishment of manufacturing facility in overseas. It is situated at Nusajaya, a premier biotechnology park and ecosystem in Johor. The facility is intended for manufacturing insulin products. In 2017, the Malaysian facility will begin to obtain approvals from the regulation authorities around the world to market its products globally, starting with the emerging markets before moving on to developed markets in later years. The facility is anticipating to commence commercial operations in the second half of 2017.

Biocon FZ LLC

Based in Dubai, Biocon FZ LLC is a subsidiary of Biocon Limited. It was incorporated in June 2015 and is engaged in marketing activities for Biocon pharmaceutical products, targeting the GCC and Middle East markets.

3.2 Merger and Acquisition

Biocon-AxiCorp GmbH

Based in Germay, AxiCorp was acquired by Biocon Limited in 2008, holding equity stake of 70% in majority. AxiCorp is known to be one of the rapid growing German pharmaceutical marketing companies in Europe. AxiCorp then obtained license in commercialising Biocon’s biosimilar insulin and Glargine in the German market. In addition, AxiCorp won the German AOK tender for a pharmaceutical drug Metformin which creates an entry into the generics market. On 2011, Biocon divested its 70% stake in AxiCorp following its strategic alliance formed in 2010 with Pfizer Inc. of United States to commercialise biosimilar insulin and analogues (TheHinduBusinessLine.com, 2011). Due to this divestment, the licensing rights were reverted to Biocon (Biocon.com, 2013).

Biocon Biopharmaceuticals Limited

Based in Cuba, Biocon Biopharmaceuticals Limited (formerly known as Biocon Biopharmaceuticals Private Limited) was incorporated on June 2002 as a 51:49 joint venture between Biocon and CIMAB SA. CINMAB SA is a commercial branch of the CIM (Center of Molecular Immunology) in Havana, Cuba (Biocon.com, 2010). Then in 2011, Biocon SA acquired its partner CIMAB shareholding, turning all the equity share of Biocon Pharmaceuticals Limited to Biocon. Later in July 2012, Biocon Pharmaceuticals Limited was amalgamated with Biocon Limited (Biocon.com, 2016b). This allows Biocon Limited and CIM to focus on a joint development of novel human antibody for treatment of rheumatoid arthritis and psoriasis (FirstcallResearch.com, 2010).

3.3 Joint Venture

NeoBiocon FZ LLC

Based in Dubai, NeoBiocon is a joint venture established between Biocon Limited and NeoPharma, a pharmaceutical manufacturing company based in Abu Dhabi. It was incorporated in January 2008 and was a 50:50 joint venture but in July 2014, Biocon acquired additional equity stake of 1% in NeoBiocon, amounting to 51% owned subsidiary by Biocon Limited. NeoBiocon is located at Dubai Science Park, a biotechnology and research park in Dubai. The purpose of this joint venture is to develop, manufacture and market a selection of biopharmaceutical drugs in the Middle East and GCC markets. NeoBiocon also offers biological, in-licensed or propriety products, research-based differentiated formulations, targeted therapeutic segments, and innovative systems for drug delivery. In 2008, NeoBiocon and Abraxis Bioscience launched Abraxane in India and the UAE for breast cancer treatment (Biocon.com, 2016b). In 2015, NeoBiocon also partnered with Novartis Middle East FZE to market anti-diabetic drugs in the UAE with Novartis manufacturing in Europe and NeoBiocon marketing and distributing in the UAE (EquityBulls.com, 2015).

3.4 Strategic Partnership

Biocon and Vaccinex Inc.

Biocon and Vaccinex of United States went into a partnership in 2014 to discover and co-develop therapeutic antibody products for patients suffering from rheumatoid arthritis (chronic inflammatory disorder on small joints in hands and feet) and lymphoma (cancer). This strategic partnership allows Biocon to access to Vaccinex proprietary technology for human antibodies development while Biocon provides its expertise in the area. This partnership also strengthens Biocon’s intellectual property protection, securing its antibody pipeline (Biocon.com, 2007).

Biocon and IATRICa Inc.

Biocon and IATRICa of United States went into a partnership in 2008 to strengthen research and co-develop a new class of immunoconjugates for treatment or prevention of cancer and infectious diseases. This strategic partnership allows the use of IATRICa’s advanced biotechnology platform and leverages on Biocon’s expertise in the field of clinical research, drug development, and biologics manufacturing (Bloomberg.com, 2016b).

3.5 Strategic Alliance

Biocon and Amylin Pharmaceuticals LLC

Biocon and Amylin of United States signed a Global Development and Commercialisation Agreement in 2009 to discover, develop and commercialise a novel therapeutic drug of peptide hybrid